
PRE Stock Forecast & Price Target
PRE Analyst Ratings
Bulls say
Prenetics Global is supported by a large $1 billion growth financing from General Catalyst’s Customer Value Fund, which can fund up to 70% of IM8 marketing spend for 25 months without dilution and materially reduces balance-sheet risk. Its IM8 brand is scaling rapidly, with preliminary June revenue of about $17 million, 1Q26 revenue from continuing operations of $36 million up roughly 333% year over year, ARR near $200 million as of May 31, and FY26 revenue guidance raised to $210-$220 million. The bull case is further strengthened by strong unit economics, including a 3:1 LTV/CAC, a shift toward quarterly subscriptions that improved AOV to $240 and speeds cash collection 3x, plus clinically validated products, broad global distribution to 43 markets, and expanding product adjacencies.
Bears say
Prenetics Global is viewed negatively because its growth depends heavily on retaining subscribers and converting new customers into recurring plans, yet renewal rates, order frequency, and customer lifetime value may deteriorate if consumer preferences shift or discretionary spending weakens. The company’s largest expense is sales and marketing, and while the move toward quarterly subscriptions may improve lifetime value, it also raises acquisition costs on an absolute basis, while global shipping, warehousing, tariffs, and trade restrictions add further pressure on margins and operating results. Governance and regulatory risks also weigh on the outlook, as the company is a controlled foreign private issuer with over 50% voting power held by the Chairman and CEO, while dietary supplements face intense competition and are not FDA-approved.
This aggregate rating is based on analysts' research of Prenetics Global Ltd and is not a guaranteed prediction by Public.com or investment advice.
PRE Analyst Forecast & Price Prediction
Start investing in PRE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Prenetics Global Ltd (PRE) Forecast
PRE Analyst Forecast & Price Prediction
Start investing in PRE
Order type
Buy in
Order amount
Est. shares
0 shares